Together with the newly granted cannabis manufacture licence, the group is now able to fully participate in the global medicinal cannabis business.
SINGAPORE (Dec 5): iX Biopharma has been awarded a cannabis manufacture license from the Australian Office of Drug Control to manufacture and supply extracts and tinctures of cannabis and cannabis resins.
The specialty pharmaceutical company’s wholly-owned subsidiary, iX Syrinx, operates a TGA cGMP certified facility, and holds import and export licences for cannabis and state poisons licences.
